HRP20200161T1 - (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja - Google Patents
(r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja Download PDFInfo
- Publication number
- HRP20200161T1 HRP20200161T1 HRP20200161TT HRP20200161T HRP20200161T1 HR P20200161 T1 HRP20200161 T1 HR P20200161T1 HR P20200161T T HRP20200161T T HR P20200161TT HR P20200161 T HRP20200161 T HR P20200161T HR P20200161 T1 HRP20200161 T1 HR P20200161T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- pharmaceutically acceptable
- compound
- methylbenzyl
- piperidin
- Prior art date
Links
- UNVYDSCXINFREZ-BHDDXSALSA-N (3R)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O UNVYDSCXINFREZ-BHDDXSALSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- -1 Compound 4-((3S,4S)-3-fluoro-1-((R)-1-(4-methylbenzyl)-2-oxopyrrolidin-3-yl)piperidin-4-yl)phenyl dihydrogen phosphate Chemical class 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (6)
1. Spoj 4-((3S,4S)-3-fluoro-1-((R)-1-(4-metilbenzil)-2-oksopirolidin-3-il)piperidin-4-il)fenil dihidrogen fosfat, koji ima formulu
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutska kompozicija koja sadrži spoj iz patentnog zahtjeva 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
3. Spoj iz patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol za primjenu u metodi za liječenje depresije, Alzheimerove bolesti, neuropatske boli, ili Parkinsonove bolesti.
4. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu iz patentnog zahtjeva 3 usmjerenu na liječenje depresije.
5. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu iz patentnog zahtjeva 3 usmjerenu na liječenje Alzheimerove bolesti.
6. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu iz patentnog zahtjeva 3 usmjerenu na liječenje neuropatske boli.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925405P | 2014-01-09 | 2014-01-09 | |
| PCT/US2015/010552 WO2015105929A1 (en) | 2014-01-09 | 2015-01-08 | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| EP15702312.8A EP3092223B1 (en) | 2014-01-09 | 2015-01-08 | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200161T1 true HRP20200161T1 (hr) | 2020-05-01 |
Family
ID=52444626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200161TT HRP20200161T1 (hr) | 2014-01-09 | 2020-01-31 | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja |
Country Status (26)
| Country | Link |
|---|---|
| US (10) | US9187506B2 (hr) |
| EP (2) | EP3092223B1 (hr) |
| JP (1) | JP6629738B2 (hr) |
| KR (1) | KR102331120B1 (hr) |
| AR (1) | AR102019A1 (hr) |
| AU (1) | AU2015204785A1 (hr) |
| CA (1) | CA2936338A1 (hr) |
| CL (1) | CL2016001744A1 (hr) |
| CY (1) | CY1122768T1 (hr) |
| DK (1) | DK3092223T3 (hr) |
| EA (1) | EA201691133A1 (hr) |
| ES (1) | ES2771825T3 (hr) |
| HR (1) | HRP20200161T1 (hr) |
| HU (1) | HUE048750T2 (hr) |
| IL (1) | IL246596A0 (hr) |
| LT (1) | LT3092223T (hr) |
| MX (1) | MX2016008715A (hr) |
| PE (1) | PE20160898A1 (hr) |
| PL (1) | PL3092223T3 (hr) |
| PT (1) | PT3092223T (hr) |
| RS (1) | RS59858B1 (hr) |
| SG (1) | SG11201605620QA (hr) |
| SI (1) | SI3092223T1 (hr) |
| TW (1) | TW201612169A (hr) |
| UY (1) | UY35946A (hr) |
| WO (1) | WO2015105929A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| CA3001894A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| EP3362441B1 (en) | 2015-10-14 | 2020-08-12 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| US20210110275A1 (en) * | 2019-10-11 | 2021-04-15 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| EA200200952A1 (ru) | 2000-04-26 | 2003-02-27 | Уорнер-Ламберт Компани | Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов |
| WO2003035641A1 (fr) | 2001-10-22 | 2003-05-01 | Shionogi & Co., Ltd. | Nouveau derive carbamoyl-pyrrolidone |
| CA2527093C (en) | 2003-06-04 | 2009-10-20 | Merck & Co., Inc. | 3-fluoro-piperidines as nmda/nr2b antagonists |
| EP1673367A1 (en) * | 2003-10-08 | 2006-06-28 | Pfizer, Inc. | Fused lactam compounds |
| WO2007099828A1 (ja) * | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
| EP2170334B1 (en) | 2007-06-29 | 2021-03-17 | Emory University | Nmda receptor antagonists for neuroprotection |
| NZ585332A (en) * | 2007-11-13 | 2012-05-25 | Vertex Pharma | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
-
2015
- 2015-01-07 US US14/591,372 patent/US9187506B2/en active Active
- 2015-01-08 WO PCT/US2015/010552 patent/WO2015105929A1/en active Application Filing
- 2015-01-08 MX MX2016008715A patent/MX2016008715A/es unknown
- 2015-01-08 TW TW104100590A patent/TW201612169A/zh unknown
- 2015-01-08 CA CA2936338A patent/CA2936338A1/en not_active Abandoned
- 2015-01-08 AU AU2015204785A patent/AU2015204785A1/en not_active Abandoned
- 2015-01-08 JP JP2016545818A patent/JP6629738B2/ja active Active
- 2015-01-08 SI SI201531064T patent/SI3092223T1/sl unknown
- 2015-01-08 PT PT157023128T patent/PT3092223T/pt unknown
- 2015-01-08 EP EP15702312.8A patent/EP3092223B1/en active Active
- 2015-01-08 KR KR1020167021355A patent/KR102331120B1/ko active IP Right Grant
- 2015-01-08 PE PE2016001105A patent/PE20160898A1/es unknown
- 2015-01-08 SG SG11201605620QA patent/SG11201605620QA/en unknown
- 2015-01-08 HU HUE15702312A patent/HUE048750T2/hu unknown
- 2015-01-08 ES ES15702312T patent/ES2771825T3/es active Active
- 2015-01-08 DK DK15702312.8T patent/DK3092223T3/da active
- 2015-01-08 EA EA201691133A patent/EA201691133A1/ru unknown
- 2015-01-08 LT LTEP15702312.8T patent/LT3092223T/lt unknown
- 2015-01-08 RS RS20200109A patent/RS59858B1/sr unknown
- 2015-01-08 EP EP19212924.5A patent/EP3677578A1/en not_active Withdrawn
- 2015-01-08 PL PL15702312T patent/PL3092223T3/pl unknown
- 2015-01-09 UY UY0001035946A patent/UY35946A/es unknown
- 2015-01-09 AR ARP150100067A patent/AR102019A1/es unknown
- 2015-10-13 US US14/881,932 patent/US20160030456A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246596A patent/IL246596A0/en unknown
- 2016-07-07 CL CL2016001744A patent/CL2016001744A1/es unknown
- 2016-11-21 US US15/357,102 patent/US20170065573A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,558 patent/US20170216325A1/en not_active Abandoned
- 2017-08-17 US US15/679,847 patent/US20170340653A1/en not_active Abandoned
- 2017-12-19 US US15/846,914 patent/US20180104265A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,049 patent/US20180250316A1/en not_active Abandoned
- 2018-12-19 US US16/225,631 patent/US20190125770A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,843 patent/US20190314392A1/en not_active Abandoned
-
2020
- 2020-01-31 HR HRP20200161TT patent/HRP20200161T1/hr unknown
- 2020-01-31 US US16/778,960 patent/US20200297742A1/en not_active Abandoned
- 2020-02-07 CY CY20201100120T patent/CY1122768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200161T1 (hr) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja | |
| ECSP19053616A (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| CY1123569T1 (el) | Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer | |
| CY1124848T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291 | |
| PH12018500259A1 (en) | Muscarinic agonists | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
| EA201890525A1 (ru) | Кристаллическая форма 2-(2,6-дихлорфенил)-1-[(1s,3r)-3-(гидроксиметил)-5-(3-гидрокси-3-метилбутил)-1-метил-3,4-дигидроизохинолин-2(1h)-ил]этанона для лечения болезни паркинсона | |
| PH12015502676A1 (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
| UY33376A (es) | Sal de tipo hemifumarato | |
| TN2015000275A1 (fr) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| JP2017503804A5 (hr) | ||
| MX2016008968A (es) | Compuestos organicos. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| BR112017020180A2 (pt) | derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer | |
| BR112016029604A2 (pt) | ?sais farmaceuticamente aceitáveis, forma cristalina, padrão cristalino, composições farmacêuticas, sais de glucamina, utilização de um sal e de uma composição farmacêutica, método para o tratamento do câncer e composto para a utilização? | |
| MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| ZA202006126B (en) | Compounds for treating alzheimer's disease | |
| GB201819758D0 (en) | Medicine for the treatment of Alzheimer's disease | |
| AU2018903530A0 (en) | Treatment for Alzheimer's Disease | |
| TH167631B (th) | วิธีการบำบัดโรคอัลไซเมอร์และองค์ประกอบทางเภสัชกรรมของมัน |